Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
Compositions and methods are provided to identify functional mutant ribosomes that may be used as drug targets. The compositions and methods allow isolation and analysis of mutations that would normally be lethal and allow direct selection of rRNA mutants with predetermined levels of ribosome function. The compositions and methods of the present invention may be used to identify antibiotics to treat a large number of human pathogens through the use of genetically engineered rRNA genes from a variety of species. The invention further provides novel plasmid constructs to be used in the methods of the invention.
1. A method for identifying functional mutant ribosomes that may be suitable as drug targets comprising:
(a) transforming a first set of host cells with a first set of plasmids, each plasmid comprising a first mutant rRNA gene and a first selectable marker gene;
wherein said first mutant rRNA gene comprises at least one mutation in addition to a first mutant ribosome binding sequence; and said first selectable marker gene comprises a first mutant message binding sequence; and
wherein said first mutant ribosome binding sequence and said first mutant message binding sequence are a mutually compatible pair;
thereby forming a first set of transformed host cells;
(b) isolating from the first set of transformed host cells those host cells which express the selectable marker gene product; and
(c) sequencing the first mutant rRNA gene from each host cell isolated in step (b), thereby identifying functionally important target regions of interest, wherein said functionally important target regions of interest comprise nucleotide sequences of one or more nucleic acids or nucleotide motifs which are conserved in each first mutant rRNA gene sequenced;
(d) generating a second plurality of mutant rRNA genes wherein the regions of interest of step (c) are mutated; and each rRNA gene further comprises a second mutant ribosome binding sequence;
(e) inserting the second plurality of mutant rRNA genes comprising the mutated regions of interest from step (d) into a second plurality of plasmids; wherein said plasmids further comprise a second genetically engineered gene which encodes a second selectable marker having a second mutant message binding sequence, wherein the second mutant ribosome binding sequence and the second mutant message binding sequence are a mutually compatible pair;
(f) transforming a second set of host cells with the plasmids from step (e), thereby forming a second set of transformed host cells;
(g) isolating from the second set of transformed host cells of step (f) those host cells which express the selectable marker gene product; and
(h) sequencing the rRNA gene from each host cell isolated in step (g), thereby identifying functional mutant ribosomes that may be suitable as drug targets.
2. A method for identifying functional mutant ribosomes that may be suitable as drug targets comprising:
(a) transforming a first set of host cells with a first set of plasmids, each plasmid comprising a first mutant E. coli 16S rRNA gene and a first green fluorescent protein gene;
wherein said first mutant E. coli 16S rRNA gene comprises at least one mutation in addition to a first mutant Anti-Shine-Dalgarno sequence; and said first green fluorescent protein gene comprises a mutant Shine-Dalgarno sequence; and
wherein said first mutant Anti-Shine-Dalgarno and said first mutant Shine-Dalgarno sequence are a mutually compatible pair;
thereby forming a first set of transformed host cells;
(b) isolating from the first set of transformed host cells those host cells which express the first green fluorescent protein gene product; and
(c) sequencing the first mutant E. coli 16S rRNA gene from each host cell isolated in step (b), thereby identifying functionally important target regions of interest, wherein said functionally important target regions of interest comprise nucleotide sequences of one or more nucleic acids or nucleotide motifs which are conserved in each first mutant E. coli 16S rRNA gene sequenced;
(d) generating a second plurality of mutant E. coli 16S rRNA genes wherein the regions of interest of step (c) are mutated; and each E. coli 16S rRNA gene further comprises a second mutant Anti-Shine-Dalgarno sequence;
(e) inserting the second plurality of mutant E. coli 16S rRNA comprising the mutated regions of interest from step (d) into a second plurality of plasmids; wherein said plasmids further comprise a second genetically engineered gene which encodes green fluorescent protein having a second mutant Shine-Dalgarno sequence, wherein the second mutant Anti-Shine-Dalgarno and the second mutant Shine-Dalgarno sequence are a mutually compatible pair;
(f) transforming a second set of host cells with the plasmids from step (e), thereby forming a second set of transformed host cells;
(g) isolating from the second set of transformed host cells of step (f) those host cells which express the second genetically engineered gene product; and
(h) sequencing the E. coli 16S rRNA gene from each host cell isolated in step (g), thereby identifying functional mutant ribosomes that may be suitable as drug targets.
3. The method of claim 1 , wherein said first mutant rRNA gene is selected from the rRNA genes of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Salmonella typhi, Yersenia pestis, Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis, Chlamydia trachomatis, Saccharomyces cerevesiae, Candida albicans , and trypanosomes.
4. The method of claim 1 , wherein said first mutant rRNA gene is a 16S rRNA gene.
5. The method of claim 1 , wherein the first selectable marker is selected from the group consisting of chloramphenicol acetyltransferase (CAT), or green fluorescent protein (GFP), or both.
6. The method of claim 1 , wherein the first selectable marker gene is green fluorescent protein.
7. The method of claim 1 , wherein the second selectable marker is selected from the group consisting of chloramphenicol acetyltransferase (CAT), or green fluorescent protein (GFP), or both.
8. The method of claim 1 , wherein the second selectable marker gene is green fluorescent protein.
9. The method of claim 1 , wherein said first mutant Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159; and said first mutant Anti-Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159.
10. The method of claim 1 , wherein said second mutant Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159; and said second mutant Anti-Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159.
11. The method of claim 2 , wherein said first mutant Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159; and said first mutant Anti-Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159.
12. The method of claim 2 , wherein said second mutant Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159; and said second mutant Anti-Shine-Dalgarno sequence is selected from the group consisting of the sequences set forth in SEQ. ID. NOS: 24-159.
13. The method of claim 1 , wherein said message binding sequence is a Shine Dalgarno sequence; said ribosome binding sequence is an Anti-Shine Dalgarno sequence; and said first mutant rRNA gene is selected from the rRNA genes of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Salmonella typhi, Yersenia pestis, Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis , and Chlamydia trachomatis.